Théa
Iolyx Therapeutics Enters Strategic Agreement with Laboratoires Théa to Develop and Commercialize ILYX-002 intended for the Treatment of Autoimmune Associated Dry Eye Disease and Secures Series B Funding for Retinal Pipeline.
12/4/25
Théa
Sepul Bio: Théa’s Innovative Unit Doses First in Phase 3 HYPERION Trial for LCA10
10/1/25
Pathology
/
Innovation
Théa Opens a New Chapter in Retinal Diseases
9/29/25
International
A new chapter for the Nordic region
8/28/25
Welcome to our testimonials section. Discover the inspiring stories of our employees, managers and healthcare professionals who share their experience with Laboratoires Théa.
Théa and you
Joining Théa means opening your eyes to opportunities for professional development. Training, career development, international mobility... our skills development program supports you throughout your career.
Join us!
Ready to join the Théa adventure? We're looking for profiles and personalities ready to innovate, whatever their field of expertise.
